Vibegron in pediatric patients with refractory daytime urinary incontinence
Connect2Clinic
![Connect2Clinic]()
Connect2Clinic
An end-to-end Practice Management Platform that makes your In-Clinic & Online practice seamless!
This study evaluated the effectiveness of Vibegron in 57 pediatric patients with daytime urinary incontinence (DUI), including refractory cases. After 6 months, the overall response rate was 68.3%, with a higher response in cases without prior anticholinergic use (85%) and those with neurodevelopmental disorders (72%). Vibegron was effective as both first-line and switch therapy but less effective when combined with anticholinergics. No significant risk factors for refractory cases were identified, highlighting vibegron’s potential in pediatric DUI treatment.
These findings highlight a promising advancement in pediatric care for DUI. It's exciting to see how Vibegron can offer faster relief, especially for children with refractory cases. Looking forward to seeing how this treatment evolves in clinical practice!